Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 57

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 57
---
 seemed to provide the best prospect for maximizing
shareholder value while preserving the flexibility to continue pursuing potential dispositions of specific assets. On August 15, 2025, the Transaction Committee approved outreach by Leerink Partners to potential financial buyers, including XRC.

In late August 2025, as Party A was notified of Party B’s superior offer for the acquisition of
RP-3467, Party A exited the process. From September through early October 2025, Party B continued due diligence and held several internal governance calls related to the asset purchase of RP-3467.

On or around August 25, 2025, at the direction of the Board, members of management and
representatives of Leerink Partners contacted two parties, including XRC and another prospective financing buyer (“Party D”) to gauge interest in acquiring the Company through a cash acquisition.

On August 27, 2025, the Company and XRC executed a confidentiality agreement in the form previously provided by Leerink Partners to XRC
(which included customary standstill provisions). XRC and certain representatives of its external counsel, Gibson Dunn & Crutcher LLP (“Gibson Dunn”) were provided with access to the Company’s virtual data
room. Further, representatives of XRC met with senior members of the Company’s management and Leerink Partners, to discuss certain due diligence topics, including the assumptions reflected in, and details with regard to, the Company’s
net cash forecast and the wind-down costs related to the Company’s clinical programs. Additional due diligence review of non-public information regarding the Company was performed and discussions of this
information with management occurred on an ongoing basis until execution of the Agreement.

On September 2, 2025, the Company and
Party D executed a confidentiality agreement in the form previously provided by Leerink Partners to Party D (which included customary standstill provisions). Party D and certain representatives of its external counsel were provided with access to
the Company’s virtual data room. Further, representatives of Party D met with senior members of the Company’s management, and Leerink Partners to discuss certain due diligence topics, including the assumptions reflected in, and details
with regard to, the Company’s net cash forecast and the wind-down costs related to the Company’s clinical programs.

On
September 19, 2025, XRC provided a non-binding indication of interest for the acquisition of the Company through a plan of arrangement. The proposal indicated that XRC, or an affiliate, would be willing
to acquire the Company for net